Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
Por:
Bento L, Gutiérrez A, Martinez C, Verdet MCO, Sorribes Portella M, Caballero Gonzalez AC, Peña M, Pérez A, Jiménez-Ubieto A, Medina L, Bastos Oreiro MB, Fernández Caldas-González P, Navarro MB, Salcedo I, Abrisqueta P, Español I, Cornago Navascués J, Martin-Moro F, García Tomás L, Gómez-Prieto P, Varela MR, Puente M, Zanabili J, Zudaire T, Zeberio I, Del Campo R, González Pinedo L, Gonzalez-Sierra PA, Blázquez-Goñi C, Rovira J, Sitges M, Franch-Sarto M, Cabero Martínez A, Mussetti A, Montoro J, Sampol A, Sureda A, Caballero-Barrigon D, Martin Garcia-Sancho AM
Publicada:
8 jul 2025
Ahead of Print:
31 mar 2025
Resumen:
We performed a retrospective multicenter study including 791 patients with relapsed/ refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as >= 3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as >= 3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.
Filiaciones:
Bento L:
Hospital Universitari Son Espases, Palma, Spain
Gutiérrez A:
Hospital Universitari Son Espases, Palma, Spain
Martinez C:
Hospital Clinic, Institute of Hematology & Oncology
Verdet MCO:
Hematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
Sorribes Portella M:
Hospital Santa Creu i Sant Pau, Barcelona, Barcelona, Spain
Caballero Gonzalez AC:
Hospital Santa Creu i Sant Pau, Barcelona, Spain
Peña M:
Hematology Department, Hospital Duran i Reynals-Institut Català d'Oncologia-Hospitalet, L'Hospitalet De Llobregat, Spain
Pérez A:
Hematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
Jiménez-Ubieto A:
Hospital Universitario 12 de Octubre, Madrid, Spain
Medina L:
Hospital Universitario 12 de Octubre, Madrid, Spain
Bastos Oreiro MB:
Hospital Universitario Gregorio Marañón, Madrid, Spain
Fernández Caldas-González P:
Hospital Universitario Gregorio Marañón, Madrid, Spain
Navarro MB:
Hospital Universitario Puerta de Hierro
Salcedo I:
Hospital Universitario Puerta de Hierro, Majadahondasp, Spain
Abrisqueta P:
Hospital Vall Hebron, Barcelona, Spain
Español I:
Hematology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
Cornago Navascués J:
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Martin-Moro F:
Department of Haematology, Ramón y Cajal University Hospital / Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain
García Tomás L:
Hospital Morales Meseguer, Murcia, Spain
Gómez-Prieto P:
H. Universitairo La Paz, Madrid, Spain
Varela MR:
Hospital Universitario de A Coruna, Coruña, Spain
Puente M:
Hospital Universitario Marqués de Valdecilla, Santander, Spain
Zanabili J:
Hospital Universitario Central de Asturias, Oviedo, Spain
Zudaire T:
Hospital Universitario de Navarra, Pamplona, Spain
Zeberio I:
Hospital Universitario de Donostia, San Sebastian, Spain
Del Campo R:
Hospital Son Llatzer
González Pinedo L:
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
Gonzalez-Sierra PA:
Hospital Universitario Virgen de las Nieves, Granada, Spain
Blázquez-Goñi C:
Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS) /CSIC, Universidad de Sevilla, Sevilla, Spain
Rovira J:
Hospital Universitari de Tarragona Joan XXIII, Institut Català d`Oncologia, Tarragona, Spain
Sitges M:
Hospital Universitari Doctor Josep Trueta, Institut Català d'Oncologia, Girona, Spain
Franch-Sarto M:
Hospital Universitari Germans Trias i Pujol, Badalona, Alabama, Spain
Cabero Martínez A:
Hematology Department. Hospital Universitario de Salamanca (Spain), IBSAL, CIBERONC. Centro de Investigación del Cáncer-IBMCC (Universidad de SalamancaCSIC)., Salamanca, Spain
Mussetti A:
Institut Català d'Oncologia-Hospitalet, L'Hospitalet De Llobregat, Spain
Montoro J:
Hospital Universitario y Politécnico La Fe, Valencia, Spain
Sampol A:
Hospital Universitario Son Espases, Palma de Mallorca, Spain
Sureda A:
Institut Català d'Oncologia, Barcelona, Spain
Caballero-Barrigon D:
Hospital Universitario de Salamanca
Martin Garcia-Sancho AM:
Hospital Universitario De Salamanca, Salamanca, Spain
Green Submitted, gold
|